Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TRC102

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
2518Background: TRC102 inhibits BER by binding to abasic sites and acting as a topo II poison to cause DNA strand breaks; it… Expand
  • figure 4
Is this relevant?
2012
2012
SummaryIntroduction TRC102 potentiates the activity of cancer therapies that induce base excision repair (BER) including… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2012
2012
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Background: MX is the first base excision repair… Expand
Is this relevant?
2012
2012
Background: MX is the first base excision repair (BER) inhibitor evaluated in humans. MX blocks the BER pathway by covalently… Expand
Is this relevant?
2010
2010
2576 Background: TRC102 is a small-molecule inhibitor of base-excision repair (BER) that is nearly completely bioavailable after… Expand
Is this relevant?
2010
2010
e13662 Background: MX, the first base excision repair (BER) inhibitor evaluated in humans, blocks the BER pathway by covalently… Expand
Is this relevant?
2010
2010
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Melanoma, the most fatal skin cancer, has… Expand
Is this relevant?
2009
2009
2552 Background: TRC102 (methoxyamine) is a small molecule inhibitor of base-excision repair (BER) that enhances the cytotoxicity… Expand
Is this relevant?
2007
2007
13005 Background: TRC102 (methoxyamine) reverses resistance to alkylating agents by inhibiting base excision repair (BER; a… Expand
Is this relevant?